

# TNBCtype: A Subtyping Tool for Triple-Negative Breast

Cancer Informatics

11, CIN.S9983

DOI: [10.4137/cin.s9983](https://doi.org/10.4137/cin.s9983)

Citation Report

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | Another review on triple negative breast cancer. Are we on the right way towards the exit from the labyrinth?. Breast, 2013, 22, 1026-1033.  | 0.9 | 43        |
| 2  | Patient-derived breast tumor xenografts facilitating personalized cancer therapy. Breast Cancer Research, 2013, 15, 201.   | 2.2 | 80        |
| 3  | Tackling the Diversity of Triple-Negative Breast Cancer. Clinical Cancer Research, 2013, 19, 6380-6388.  | 3.2 | 141       |
| 4  | Next-generation sequencing: a powerful tool for the discovery of molecular markers in breast ductal carcinoma <i>in situ</i> . Expert Review of Molecular Diagnostics, 2013, 13, 151-165.  | 1.5 | 40        |
| 5  | Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes. Clinical Cancer Research, 2013, 19, 5533-5540.   | 3.2 | 597       |
| 6  | Development of targeted therapies for triple-negative breast cancer: can we harness tumor heterogeneity to improve patient outcomes?. Breast Cancer Management, 2013, 2, 175-178.  | 0.2 | 0         |
| 7  | Mislocalization of the Cell Polarity Protein Scribble Promotes Mammary Tumorigenesis and Is Associated with Basal Breast Cancer. Cancer Research, 2014, 74, 3180-3194.   | 0.4 | 97        |
| 8  | Development of Human Serine Protease-Based Therapeutics Targeting Fn14 and Identification of Fn14 as a New Target Overexpressed in TNBC. Molecular Cancer Therapeutics, 2014, 13, 2688-2705.                                       | 1.9 | 24        |
| 9  | RMA with quantile normalization mixes biological signals between different sample groups in microarray data analysis. , 2014, , .  |     | 5         |
| 10 | New Strategies in Breast Cancer: The Significance of Molecular Subtypes in Systemic Adjuvant Treatment for Small T1a,bN0M0 Tumors. Clinical Cancer Research, 2014, 20, 6242-6246.  | 3.2 | 15        |
| 11 | Receptor-interacting protein kinase 2 promotes triple-negative breast cancer cell migration and invasion via activation of nuclear factor- $\kappa$ B and c-Jun N-terminal kinase pathways. Breast Cancer Research, 2014, 16, R28. | 2.2 | 43        |
| 12 | IL15RA Drives Antagonistic Mechanisms of Cancer Development and Immune Control in Lymphocyte-Enriched Triple-Negative Breast Cancers. Cancer Research, 2014, 74, 4908-4921.  | 0.4 | 39        |
| 13 | DupChecker: a bioconductor package for checking high-throughput genomic data redundancy in meta-analysis. BMC Bioinformatics, 2014, 15, 323.   | 1.2 | 3         |
| 14 | Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition. Breast Cancer Research, 2014, 16, R36.  | 2.2 | 63        |
| 15 | Causal Network Models for Predicting Compound Targets and Driving Pathways in Cancer. Journal of Biomolecular Screening, 2014, 19, 791-802.  | 2.6 | 23        |
| 16 | Androgenic pathways in the progression of triple-negative breast carcinoma: a comparison between aggressive and non-aggressive subtypes. Breast Cancer Research and Treatment, 2014, 145, 281-293.                                 | 1.1 | 34        |
| 17 | IDO is highly expressed in breast cancer and breast cancer-derived circulating microvesicles and associated to aggressive types of tumors by <i>in silico</i> analysis. Tumor Biology, 2014, 35, 6511-6519.                        | 0.8 | 45        |
| 18 | Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes. Journal of Pathology, 2014, 232, 142-150.   | 2.1 | 354       |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Emerging Prognostic and Predictive Biomarkers for Triple Negative Breast Cancer. <i>Current Breast Cancer Reports</i> , 2014, 6, 275-282.  | 0.5 | 1         |
| 20 | New Strategies for Triple-Negative Breast Cancer—Deciphering the Heterogeneity. <i>Clinical Cancer Research</i> , 2014, 20, 782-790.   | 3.2 | 242       |
| 21 | PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors. <i>Breast Cancer Research</i> , 2014, 16, 406.                  | 2.2 | 267       |
| 22 | Molecular features of the basal-like breast cancer subtype based on BRCA1 mutation status. <i>Breast Cancer Research and Treatment</i> , 2014, 147, 185-191.   | 1.1 | 37        |
| 23 | Breast Cancer Disparities. <i>Surgical Oncology Clinics of North America</i> , 2014, 23, 579-592.  | 0.6 | 50        |
| 24 | Triple-Negative Breast Cancer: One Or More Entities?. <i>Forum of Clinical Oncology</i> , 2014, 5, 20-31.  | 0.1 | 1         |
| 25 | Treating Triple-Negative Breast Cancer: Where Are We?. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, e8-e18.  | 2.3 | 1         |
| 26 | Advances of Non-Surgical Therapy for Different Molecular Subtypes of Breast Cancer. <i>Advancements in Genetic Engineering</i> , 2015, 04, .   | 0.1 | 0         |
| 27 | Molecular Features of Triple Negative Breast Cancer: Microarray Evidence and Further Integrated Analysis. <i>PLoS ONE</i> , 2015, 10, e0129842.  | 1.1 | 17        |
| 28 | Genomic profiling of breast cancers. <i>Current Opinion in Obstetrics and Gynecology</i> , 2015, 27, 34-39.  | 0.9 | 19        |
| 29 | BRCA1-like signature in triple negative breast cancer: Molecular and clinical characterization reveals subgroups with therapeutic potential. <i>Molecular Oncology</i> , 2015, 9, 1528-1538.                                 | 2.1 | 54        |
| 30 | Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy. <i>BMC Medicine</i> , 2015, 13, 303.   | 2.3 | 113       |
| 31 | Adjuvant systemic therapy in breast cancer: quo vadis?. <i>Annals of Oncology</i> , 2015, 26, 1629-1634.   | 0.6 | 18        |
| 32 | Biologic, Demographic, and Social Factors Affecting Triple Negative Breast Cancer Outcomes. <i>Clinical Journal of Oncology Nursing</i> , 2015, 19, 62-67.   | 0.3 | 8         |
| 33 | Therapies for triple negative breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 983-998.   | 0.9 | 85        |
| 34 | Mouse mammary stem cells express prognostic markers for triple-negative breast cancer. <i>Breast Cancer Research</i> , 2015, 17, 31.   | 2.2 | 35        |
| 35 | Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response. <i>Breast Cancer Research</i> , 2015, 17, 43.   | 2.2 | 248       |
| 36 | Characterizing Breast Cancer in a Population with Increased Prevalence of Triple-Negative Breast Cancer: Androgen Receptor and ALDH1 Expression in Ghanaian Women. <i>Annals of Surgical Oncology</i> , 2015, 22, 3831-3835. | 0.7 | 27        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 37 | TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 2722-2729. | 3.2 | 57        |
| 38 | Disparities in Breast Cancer and African Ancestry: A Global Perspective. <i>Breast Journal</i> , 2015, 21, 133-139.   | 0.4 | 52        |
| 39 | Of Mice and Women: A Comparative Tissue Biology Perspective of Breast Stem Cells and Differentiation. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2015, 20, 51-62.  | 1.0 | 44        |
| 40 | Stratifying triple-negative breast cancer prognosis using 18F-FDG-PET/CT imaging. <i>Breast Cancer Research and Treatment</i> , 2015, 153, 607-616.   | 1.1 | 22        |
| 41 | Comparison of the Genomic Landscape Between Primary Breast Cancer in African American Versus White Women and the Association of Racial Differences With Tumor Recurrence. <i>Journal of Clinical Oncology</i> , 2015, 33, 3621-3627.                  | 0.8 | 172       |
| 42 | Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 1688-1698.   | 3.2 | 990       |
| 43 | RNA Sequencing of Formalin-Fixed, Paraffin-Embedded Specimens for Gene Expression Quantification and Data Mining. <i>International Journal of Genomics</i> , 2016, 2016, 1-10.  | 0.8 | 15        |
| 44 | Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection. <i>PLoS ONE</i> , 2016, 11, e0157368.  | 1.1 | 975       |
| 45 | Stratification of Prognosis of Triple-Negative Breast Cancer Patients Using Combinatorial Biomarkers. <i>PLoS ONE</i> , 2016, 11, e0149661.   | 1.1 | 25        |
| 46 | Molecular Classification of Triple-Negative Breast Cancer. <i>Journal of Breast Cancer</i> , 2016, 19, 223.   | 0.8 | 111       |
| 47 | A novel EGR1 dependent mechanism for YB1 modulation of paclitaxel response in a triple negative breast cancer cell line. <i>International Journal of Cancer</i> , 2016, 139, 1157-1170.   | 2.3 | 32        |
| 48 | Comprehensive transcriptome analysis identifies novel molecular subtypes and subtype-specific RNAs of triple-negative breast cancer. <i>Breast Cancer Research</i> , 2016, 18, 33.  | 2.2 | 176       |
| 49 | <sup>125</sup> I-NP63 induces quiescence and downregulates the BRCA1 pathway in estrogen receptor-positive luminal breast cancer cell line MCF7 but not in other breast cancer cell lines. <i>Molecular Oncology</i> , 2016, 10, 575-593.             | 2.1 | 20        |
| 50 | Development of mouse models of malignant phyllodes tumors by transplantation of syngeneic mammary gland cells expressing mutant H-Ras. <i>Genes To Cells</i> , 2016, 21, 1244-1252.   | 0.5 | 2         |
| 51 | Novel insight into triple-negative breast cancers, the emerging role of angiogenesis, and antiangiogenic therapy. <i>Expert Reviews in Molecular Medicine</i> , 2016, 18, e18.  | 1.6 | 36        |
| 52 | Brief exposure to preoperative bevacizumab reveals a TGFβ2 signature predictive of response in HER2-negative breast cancers. <i>International Journal of Cancer</i> , 2016, 138, 747-757.   | 2.3 | 16        |
| 53 | The Role of Proliferation in Determining Response to Neoadjuvant Chemotherapy in Breast Cancer: A Gene Expression-Based Meta-Analysis. <i>Clinical Cancer Research</i> , 2016, 22, 6039-6050.   | 3.2 | 48        |
| 54 | RANKL/RANK control Brca1 mutation-driven mammary tumors. <i>Cell Research</i> , 2016, 26, 761-774.  | 5.7 | 128       |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 55 | Maximiscin Induces DNA Damage, Activates DNA Damage Response Pathways, and Has Selective Cytotoxic Activity against a Subtype of Triple-Negative Breast Cancer. <i>Journal of Natural Products</i> , 2016, 79, 1822-1827.  | 1.5 | 22        |
| 56 | PI3K-AKT-mTOR Pathway Cooperates with the DNA Damage Repair Pathway: Carcinogenesis in Triple-Negative Breast Cancers and Beyond. <i>Cancer Drug Discovery and Development</i> , 2016, , 65-108.   | 0.2 | 0         |
| 57 | Expression of the MHC Class II Pathway in Triple-Negative Breast Cancer Tumor Cells Is Associated with a Good Prognosis and Infiltrating Lymphocytes. <i>Cancer Immunology Research</i> , 2016, 4, 390-399.  | 1.6 | 112       |
| 58 | Biological network-driven gene selection identifies a stromal immune module as a key determinant of triple-negative breast carcinoma prognosis. <i>Oncolmmunology</i> , 2016, 5, e1061176.   | 2.1 | 30        |
| 59 | Clinical and molecular relevance of mutant-allele tumor heterogeneity in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 162, 39-48.  | 1.1 | 47        |
| 60 | GATA3 expression in triple-negative breast cancers. <i>Histopathology</i> , 2017, 71, 63-71.   | 1.6 | 18        |
| 61 | A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67. <i>Clinical Cancer Research</i> , 2017, 23, 4035-4045. | 3.2 | 104       |
| 62 | Pentraxin-3 is a PI3K signaling target that promotes stem cell-like traits in basal-like breast cancers. <i>Science Signaling</i> , 2017, 10, .  | 1.6 | 43        |
| 63 | Comparison of triple-negative breast cancer molecular subtyping using RNA from matched fresh-frozen versus formalin-fixed paraffin-embedded tissue. <i>BMC Cancer</i> , 2017, 17, 241.   | 1.1 | 27        |
| 64 | Cell state plasticity, stem cells, EMT, and the generation of intra-tumoral heterogeneity. <i>Npj Breast Cancer</i> , 2017, 3, 14.   | 2.3 | 115       |
| 65 | Expression of Nestin associates with BRCA1 mutations, a basal-like phenotype and aggressive breast cancer. <i>Scientific Reports</i> , 2017, 7, 1089.  | 1.6 | 19        |
| 66 | Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer. <i>Nature Communications</i> , 2017, 8, 15081.  | 5.8 | 743       |
| 67 | Single-Cell Dynamics Determines Response to CDK4/6 Inhibition in Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 5561-5572.   | 3.2 | 198       |
| 68 | A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors. <i>Clinical Cancer Research</i> , 2017, 23, 6468-6477.  | 3.2 | 48        |
| 69 | Nanogrid single-nucleus RNA sequencing reveals phenotypic diversity in breast cancer. <i>Nature Communications</i> , 2017, 8, 228.   | 5.8 | 105       |
| 70 | UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. <i>Neoplasia</i> , 2017, 19, 649-658.  | 2.3 | 4,166     |
| 71 | Interferon-beta represses cancer stem cell properties in triple-negative breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 13792-13797.   | 3.3 | 93        |
| 72 | Identification of Interacting Stromal Axes in Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2017, 77, 4673-4683.   | 0.4 | 25        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 73 | Brain Metastasis Prediction by Transcriptomic Profiling in Triple-Negative Breast Cancer. <i>Clinical Breast Cancer</i> , 2017, 17, e65-e75.  | 1.1 | 14        |
| 74 | Chemotherapy response and survival of inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes approximation: an analysis from the National Cancer Database. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 161-168. | 1.2 | 38        |
| 75 | Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients. <i>International Journal of Molecular Sciences</i> , 2017, 18, 459.  | 1.8 | 66        |
| 76 | Efficacy and Molecular Mechanisms of Differentiated Response to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Models of p53-Mutated Triple-Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2017, 7, 94.                                  | 1.3 | 19        |
| 77 | Basic Concepts in Molecular Pathologyâ€”Introduction to Molecular Testing in Human Disease. , 2017, , 3-14.   |     | 0         |
| 78 | Pathological Response in a Triple-Negative Breast Cancer Cohort Treated with Neoadjuvant Carboplatin and Docetaxel According to Lehmann's Refined Classification. <i>Clinical Cancer Research</i> , 2018, 24, 1845-1852.  | 3.2 | 84        |
| 79 | Classification of triple-negative breast cancers based on Immunogenomic profiling. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 327.   | 3.5 | 329       |
| 80 | Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy. <i>Oncotarget</i> , 2018, 9, 26406-26416.   | 0.8 | 136       |
| 81 | Rates of immune cell infiltration in patients with triple-negative breast cancer by molecular subtype. <i>PLoS ONE</i> , 2018, 13, e0204513.  | 1.1 | 34        |
| 82 | The Landscape of Small Non-Coding RNAs in Triple-Negative Breast Cancer. <i>Genes</i> , 2018, 9, 29.  | 1.0 | 21        |
| 83 | Co-expressed genes enhance precision of receptor status identification in breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2018, 172, 313-326.   | 1.1 | 7         |
| 84 | Subtyping Of Triple Negative Breast Carcinoma On The Basis Of RTK Expression. <i>Journal of Cancer</i> , 2018, 9, 2589-2602.  | 1.2 | 3         |
| 85 | Clinicopathological, immunohistochemical and molecular correlation of neural crest transcription factor SOX10 expression in triple-negative breast carcinoma. <i>Human Pathology</i> , 2018, 80, 163-169.   | 1.1 | 29        |
| 86 | Systems modelling of the EGFR-PYK2-c-Met interaction network predicts and prioritizes synergistic drug combinations for triple-negative breast cancer. <i>PLoS Computational Biology</i> , 2018, 14, e1006192.  | 1.5 | 26        |
| 87 | Identification of highly penetrant Rb-related synthetic lethal interactions in triple negative breast cancer. <i>Oncogene</i> , 2018, 37, 5701-5718.  | 2.6 | 24        |
| 88 | Integrative 3â€² Untranslated Region-Based Model to Identify Patients with Low Risk of Axillary Lymph Node Metastasis in Operable Triple-Negative Breast Cancer. <i>Oncologist</i> , 2019, 24, 22-30.   | 1.9 | 13        |
| 89 | Clinicopathological Features of Triple-Negative Breast Cancer Epigenetic Subtypes. <i>Annals of Surgical Oncology</i> , 2019, 26, 3344-3353.  | 0.7 | 15        |
| 90 | Prognostic Value of Ki-67 in Patients With Resected Triple-Negative Breast Cancer: A Meta-Analysis. <i>Frontiers in Oncology</i> , 2019, 9, 1068.   | 1.3 | 43        |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 91  | Cross comparison and prognostic assessment of breast cancer multigene signatures in a large population-based contemporary clinical series. <i>Scientific Reports</i> , 2019, 9, 12184.  | 1.6  | 39        |
| 92  | Comparison of molecular profile in triple-negative inflammatory and non-inflammatory breast cancer not of mesenchymal stem-like subtype. <i>PLoS ONE</i> , 2019, 14, e0222336.  | 1.1  | 17        |
| 93  | Whole genome sequencing of breast cancer. <i>Apmis</i> , 2019, 127, 303-315.  | 0.9  | 23        |
| 94  | TAAR1 levels and sub-cellular distribution are cell line but not breast cancer subtype specific. <i>Histochemistry and Cell Biology</i> , 2019, 152, 155-166.   | 0.8  | 12        |
| 95  | A large collection of integrated genomically characterized patient-derived xenografts highlighting the heterogeneity of triple-negative breast cancer. <i>International Journal of Cancer</i> , 2019, 145, 1902-1912.   | 2.3  | 37        |
| 96  | Classifying Breast Cancer Subtypes Using Multiple Kernel Learning Based on Omics Data. <i>Genes</i> , 2019, 10, 200.  | 1.0  | 34        |
| 97  | Triple Negative Breast Cancer Profile, from Gene to microRNA, in Relation to Ethnicity. <i>Cancers</i> , 2019, 11, 363.   | 1.7  | 35        |
| 98  | Targeting BCL-xL improves the efficacy of bromodomain and extra-terminal protein inhibitors in triple-negative breast cancer by eliciting the death of senescent cells. <i>Journal of Biological Chemistry</i> , 2019, 294, 875-886.  | 1.6  | 46        |
| 99  | Expression of long non-coding RNA ENSG00000226738 (LncKLHDC7B) is enriched in the immunomodulatory triple-negative breast cancer subtype and its alteration promotes cell migration, invasion, and resistance to cell death. <i>Molecular Oncology</i> , 2019, 13, 909-927. | 2.1  | 29        |
| 100 | Cyclic Multiplexed-Immunofluorescence (cmIF), a Highly Multiplexed Method for Single-Cell Analysis. <i>Methods in Molecular Biology</i> , 2020, 2055, 521-562.  | 0.4  | 33        |
| 101 | Aggressive Mammary Cancers Lacking Lymphocytic Infiltration Arise in Irradiated Mice and Can Be Prevented by Dietary Intervention. <i>Cancer Immunology Research</i> , 2020, 8, 217-229.  | 1.6  | 11        |
| 102 | The orphan nuclear receptor estrogen-related receptor beta (ERR $\beta$ ) in triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 179, 585-604.   | 1.1  | 8         |
| 103 | TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR+ Metastatic Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 2111-2123.  | 3.2  | 91        |
| 104 | Interpreting pathways to discover cancer driver genes with Moonlight. <i>Nature Communications</i> , 2020, 11, 69.  | 5.8  | 66        |
| 105 | Retyping of triple-negative breast cancer based on clustering method. <i>Expert Systems</i> , 2020, , e12583.   | 2.9  | 1         |
| 106 | Proteogenomic Landscape of Breast Cancer Tumorigenesis and Targeted Therapy. <i>Cell</i> , 2020, 183, 1436-1456.e31.  | 13.5 | 273       |
| 107 | Dissecting the heterogeneity of the alternative polyadenylation profiles in triple-negative breast cancers. <i>Theranostics</i> , 2020, 10, 10531-10547.  | 4.6  | 27        |
| 108 | MiRNA and LncRNA as Potential Biomarkers in Triple-Negative Breast Cancer: A Review. <i>Frontiers in Oncology</i> , 2020, 10, 526850.   | 1.3  | 78        |



| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 109 | Proteomic Resistance Biomarkers for PI3K Inhibitor in Triple Negative Breast Cancer Patient-Derived Xenograft Models. <i>Cancers</i> , 2020, 12, 3857.  | 1.7 | 8         |
| 110 | RX-5902, a novel $\beta$ -catenin modulator, potentiates the efficacy of immune checkpoint inhibitors in preclinical models of triple-negative breast Cancer. <i>BMC Cancer</i> , 2020, 20, 1063.   | 1.1 | 16        |
| 111 | Drug Repurposing for Triple-Negative Breast Cancer. <i>Journal of Personalized Medicine</i> , 2020, 10, 200.  | 1.1 | 29        |
| 112 | Identification of Distinct Heterogenic Subtypes and Molecular Signatures Associated with African Ancestry in Triple Negative Breast Cancer Using Quantified Genetic Ancestry Models in Admixed Race Populations. <i>Cancers</i> , 2020, 12, 1220. | 1.7 | 19        |
| 113 | Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer. <i>Nature Communications</i> , 2020, 11, 2662.  | 5.8 | 157       |
| 114 | Biology of the Triple-Negative Breast Cancer: Immunohistochemical, RNA, and DNA Features. <i>Breast Care</i> , 2020, 15, 208-216.   | 0.8 | 6         |
| 115 | An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers. <i>BMC Cancer</i> , 2020, 20, 197.   | 1.1 | 24        |
| 116 | Molecular Classification and Future Therapeutic Challenges of Triple-negative Breast Cancer. <i>In Vivo</i> , 2020, 34, 1715-1727.  | 0.6 | 16        |
| 117 | Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers. <i>Journal of Hematology and Oncology</i> , 2020, 13, 13.   | 6.9 | 29        |
| 118 | LncRNA RP11-19E11 is an E2F1 target required for proliferation and survival of basal breast cancer. <i>Npj Breast Cancer</i> , 2020, 6, 1.  | 2.3 | 47        |
| 119 | A Transcriptionally Definable Subgroup of Triple-Negative Breast and Ovarian Cancer Samples Shows Sensitivity to HSP90 Inhibition. <i>Clinical Cancer Research</i> , 2020, 26, 159-170.   | 3.2 | 2         |
| 120 | Functional characterization of androgen receptor in two patient-derived xenograft models of triple negative breast cancer. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2021, 206, 105791.                                      | 1.2 | 3         |
| 121 | Phase II Trial of Neoadjuvant Carboplatin and Nab-Paclitaxel in Patients with Triple-Negative Breast Cancer. <i>Oncologist</i> , 2021, 26, e382-e393.   | 1.9 | 27        |
| 123 | Molecular analyses of triple-negative breast cancer in the young and elderly. <i>Breast Cancer Research</i> , 2021, 23, 20.   | 2.2 | 23        |
| 124 | Decision theory for precision therapy of breast cancer. <i>Scientific Reports</i> , 2021, 11, 4233.   | 1.6 | 3         |
| 125 | CIBERSORT analysis of TCGA and METABRIC identifies subgroups with better outcomes in triple negative breast cancer. <i>Scientific Reports</i> , 2021, 11, 4691.   | 1.6 | 53        |
| 126 | Triple-negative breast lobular carcinoma: a luminal androgen receptor carcinoma with specific ESRRA mutations. <i>Modern Pathology</i> , 2021, 34, 1282-1296.   | 2.9 | 22        |
| 127 | Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 188, 165-178.   | 1.1 | 13        |



| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 128 | <sc>ER</sc>+ breast cancer: A distinct entity, which is morphologically and molecularly close to triple-negative breast cancer. <i>International Journal of Cancer</i> , 2021, 149, 200-213.  | 2.3 | 14        |
| 130 | LINC00460 Is a Dual Biomarker That Acts as a Predictor for Increased Prognosis in Basal-Like Breast Cancer and Potentially Regulates Immunogenic and Differentiation-Related Genes. <i>Frontiers in Oncology</i> , 2021, 11, 628027.                                      | 1.3 | 11        |
| 131 | Precision Medicine and Triple-Negative Breast Cancer: Current Landscape and Future Directions. <i>Cancers</i> , 2021, 13, 3739.   | 1.7 | 27        |
| 132 | Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 377-386. | 1.1 | 38        |
| 134 | Unveiling Novel Therapeutic Drug Targets and Prognostic Markers of Triple Negative Breast Cancer. <i>Current Cancer Drug Targets</i> , 2021, 21, 907-918.   | 0.8 | 7         |
| 135 | Recurrence biomarkers of triple negative breast cancer treated with neoadjuvant chemotherapy and anti-EGFR antibodies. <i>Npj Breast Cancer</i> , 2021, 7, 124.   | 2.3 | 7         |
| 137 | Gene expression information improves reliability of receptor status in breast cancer patients. <i>Oncotarget</i> , 2017, 8, 77341-77359.  | 0.8 | 7         |
| 138 | Differential prioritization of therapies to subtypes of triple negative breast cancer using a systems medicine method. <i>Oncotarget</i> , 2017, 8, 92926-92942.  | 0.8 | 6         |
| 139 | The TGF $\beta$ -EGFR-Akt signaling axis plays a role in enhancing proinflammatory chemokines in triple-negative breast cancer cells. <i>Oncotarget</i> , 2018, 9, 29286-29303.   | 0.8 | 12        |
| 140 | A single-nucleotide polymorphism in the 3' UTR region of the adipocyte fatty acid binding protein 4 gene is associated with prognosis of triple-negative breast cancer. <i>Oncotarget</i> , 2016, 7, 18984-18998.   | 0.8 | 13        |
| 141 | Whole transcriptome profiling of patient-derived xenograft models as a tool to identify both tumor and stromal specific biomarkers. <i>Oncotarget</i> , 2016, 7, 20773-20787.   | 0.8 | 36        |
| 142 | Fortgeschrittenes Triple-negatives Mammakarzinom: Immuntherapien in Präfung. , 0, , .   |     | 3         |
| 143 | The geographic distribution of mammography resources in Mississippi. <i>Online Journal of Public Health Informatics</i> , 2014, 5, 226.   | 0.4 | 9         |
| 144 | Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts. <i>Theranostics</i> , 2020, 10, 1531-1543.   | 4.6 | 34        |
| 145 | Breast Cancer Consensus Subtypes: A system for subtyping breast cancer tumors based on gene expression. <i>Npj Breast Cancer</i> , 2021, 7, 136.  | 2.3 | 20        |
| 146 | Identifying High-Risk Triple-Negative Breast Cancer Patients by Molecular Subtyping. <i>Breast Care</i> , 2021, 16, 637-647.  | 0.8 | 7         |
| 147 | shinySISPA: A web tool for defining sample groups using gene sets from multiple-omics data. <i>F1000Research</i> , 2018, 7, 213.  | 0.8 | 0         |
| 148 | shinySISPA: A web tool for defining sample groups using gene sets from multiple-omics data. <i>F1000Research</i> , 2018, 7, 213.  | 0.8 | 0         |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 149 | PITX2 DNA-Methylation: Predictive versus Prognostic Value for Anthracycline-Based Chemotherapy in Triple-Negative Breast Cancer Patients. <i>Breast Care</i> , 2021, 16, 523-531.   | 0.8  | 3         |
| 150 | Investigating Potential Drug Repurposing for Triple Negative Breast Cancer. <i>Trends in Applied Sciences Research</i> , 2020, 15, 242-252.   | 0.4  | 0         |
| 151 | Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes. <i>Nature Communications</i> , 2021, 12, 6276.   | 5.8  | 89        |
| 152 | Secreted indicators of androgen receptor activity in breast cancer pre-clinical models. <i>Breast Cancer Research</i> , 2021, 23, 102.  | 2.2  | 7         |
| 154 | Correlation of Notch1, pAKT and nuclear NF- $\kappa$ B expression in triple negative breast cancer. <i>American Journal of Cancer Research</i> , 2013, 3, 230-9.  | 1.4  | 22        |
| 155 | Mammary Tumor-Derived Transplants as Breast Cancer Models to Evaluate Tumor-Immune Interactions and Therapeutic Responses. <i>Cancer Research</i> , 2022, 82, 365-376.  | 0.4  | 1         |
| 156 | A triple-negative breast cancer surrogate subtype classification that correlates with gene expression subtypes. <i>Breast Cancer Research and Treatment</i> , 2022, 191, 599-610.   | 1.1  | 4         |
| 157 | The Transcriptomic Portrait of Locally Advanced Breast Cancer and Its Prognostic Value in a Multi-Country Cohort of Latin American Patients. <i>Frontiers in Oncology</i> , 2022, 12, 835626.   | 1.3  | 1         |
| 158 | Tissue-resident FOLR2+ macrophages associate with CD8+ T cell infiltration in human breast cancer. <i>Cell</i> , 2022, 185, 1189-1207.e25.  | 13.5 | 166       |
| 159 | Prognostic Impact of High Baseline Stromal Tumor-Infiltrating Lymphocytes in the Absence of Pathologic Complete Response in Early-Stage Triple-Negative Breast Cancer. <i>Cancers</i> , 2022, 14, 1323.                                 | 1.7  | 4         |
| 160 | Decision Theory versus Conventional Statistics for Personalized Therapy of Breast Cancer. <i>Journal of Personalized Medicine</i> , 2022, 12, 570.  | 1.1  | 1         |
| 161 | YB1 Is a Major Contributor to Health Disparities in Triple Negative Breast Cancer. <i>Cancers</i> , 2021, 13, 6262.   | 1.7  | 6         |
| 162 | Immune Milieu and Genomic Alterations Set the Triple-Negative Breast Cancer Immunomodulatory Subtype Tumor Behavior. <i>Cancers</i> , 2021, 13, 6256.   | 1.7  | 6         |
| 163 | Reduced Expression of Annexin A6 Induces Metabolic Reprogramming That Favors Rapid Fatty Acid Oxidation in Triple-Negative Breast Cancer Cells. <i>Cancers</i> , 2022, 14, 1108.  | 1.7  | 4         |
| 164 | Targeting regulated cell death (RCD) with small-molecule compounds in triple-negative breast cancer: a revisited perspective from molecular mechanisms to targeted therapies. <i>Journal of Hematology and Oncology</i> , 2022, 15, 44. | 6.9  | 44        |
| 165 | CmP Signaling Network Leads to Identification of Prognostic Biomarkers for Triple-Negative Breast Cancer in Caucasian Women. <i>Genetic Testing and Molecular Biomarkers</i> , 2022, 26, 198-219.                                       | 0.3  | 13        |
| 166 | Molecular Characterization and Prospective Evaluation of Pathologic Response and Outcomes with Neoadjuvant Therapy in Metaplastic Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 2878-2889.                 | 3.2  | 10        |
| 167 | Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies. <i>Cancer Cell</i> , 2022, 40, 609-623.e6.   | 7.7  | 92        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 168 | Reassessment of Reliability and Reproducibility for Triple-Negative Breast Cancer Subtyping. <i>Cancers</i> , 2022, 14, 2571.   | 1.7 | 2         |
| 169 | Aberrant calcium signalling downstream of mutations in TP53 and the PI3K/AKT pathway genes promotes disease progression and therapy resistance in triple negative breast cancer. <i>Cancer Drug Resistance (Alhambra, Calif)</i> , 2022, 5, 560-76. | 0.9 | 3         |
| 170 | Luminal androgen receptor breast cancer subtype and investigation of the microenvironment and neoadjuvant chemotherapy response. <i>NAR Cancer</i> , 2022, 4, .   | 1.6 | 10        |
| 171 | Expression and Clinical Significance of CMTM6 and PD-L1 in Triple-Negative Breast Cancer. <i>BioMed Research International</i> , 2022, 2022, 1-10.  | 0.9 | 4         |
| 172 | High PANX1 Expression Leads to Neutrophil Recruitment and the Formation of a High Adenosine Immunosuppressive Tumor Microenvironment in Basal-like Breast Cancer. <i>Cancers</i> , 2022, 14, 3369.  | 1.7 | 5         |
| 173 | Genomic and epigenomic <i>BRCA</i> alterations predict adaptive resistance and response to platinum-based therapy in patients with triple-negative breast and ovarian carcinomas. <i>Science Translational Medicine</i> , 2022, 14, .               | 5.8 | 15        |
| 174 | Prognostic Capability of TNBC 3-Gene Score among Triple-Negative Breast Cancer Subtypes. <i>Cancers</i> , 2022, 14, 4286.   | 1.7 | 2         |
| 175 | Spatial Transcriptomic Analysis of a Diverse Patient Cohort Reveals a Conserved Architecture in Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2023, 83, 34-48.  | 0.4 | 9         |
| 176 | Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, Is Highly Active Against Triple-Negative Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2023, 22, 205-214.  | 1.9 | 2         |
| 177 | Contemporary evaluation of estrogen receptor and progesterone receptor expression in breast cancer-associated stroma. <i>Breast Cancer Research and Treatment</i> , 2022, 196, 453-461.   | 1.1 | 0         |
| 178 | A Case Series Exploration of Multi-Regional Expression Heterogeneity in Triple-Negative Breast Cancer Patients. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13322.   | 1.8 | 2         |
| 179 | Race and Ancestry in Immune Response to Breast Cancer. <i>Cancer Discovery</i> , 2022, 12, 2496-2497.   | 7.7 | 1         |
| 180 | Checkpoint Kinase 1 (CHK1) Functions as Both a Diagnostic Marker and a Regulator of Epithelial-to-Mesenchymal Transition (EMT) in Triple-Negative Breast Cancer. <i>Current Issues in Molecular Biology</i> , 2022, 44, 5848-5865.                  | 1.0 | 4         |
| 181 | Identification of a minimum number of genes to predict triple-negative breast cancer subgroups from gene expression profiles. <i>Human Genomics</i> , 2022, 16, .   | 1.4 | 2         |
| 182 | Update on triple-negative breast cancers highlighting subtyping update and treatment implication. <i>Histopathology</i> , 2023, 82, 17-35.  | 1.6 | 13        |
| 183 | Predictors of success in establishing orthotopic patient-derived xenograft models of triple negative breast cancer. <i>Npj Breast Cancer</i> , 2023, 9, .   | 2.3 | 3         |
| 184 | AKR1C2 Promotes Metastasis and Regulates the Molecular Features of Luminal Androgen Receptor Subtype in Triple Negative Breast Cancer Cells. <i>Journal of Breast Cancer</i> , 2023, 26, 60.  | 0.8 | 1         |
| 185 | Theranostics for Triple-Negative Breast Cancer. <i>Diagnostics</i> , 2023, 13, 272.   | 1.3 | 7         |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 186 | Systemically Identifying Triple-Negative Breast Cancer Subtype-Specific Prognosis Signatures, Based on Single-Cell RNA-Seq Data. <i>Cells</i> , 2023, 12, 367.                               | 1.8  | 1         |
| 187 | Blood-Based mRNA Tests as Emerging Diagnostic Tools for Personalised Medicine in Breast Cancer. <i>Cancers</i> , 2023, 15, 1087.   | 1.7  | 5         |
| 188 | The tumor microenvironment and triple-negative breast cancer aggressiveness: shedding light on mechanisms and targeting. <i>Expert Opinion on Therapeutic Targets</i> , 2022, 26, 1041-1056. | 1.5  | 3         |
| 189 | Transcriptome Meta-Analysis of Triple-Negative Breast Cancer Response to Neoadjuvant Chemotherapy. <i>Cancers</i> , 2023, 15, 2194.  | 1.7  | 0         |
| 190 | CRISPR/Cas genome editing in triple negative breast cancer: Current situation and future directions. <i>Biochemical Pharmacology</i> , 2023, 209, 115449.                                    | 2.0  | 3         |
| 191 | Oncolytic T-VEC virotherapy plus neoadjuvant chemotherapy in nonmetastatic triple-negative breast cancer: a phase 2 trial. <i>Nature Medicine</i> , 2023, 29, 450-457.                       | 15.2 | 21        |
| 192 | <i>HORMAD1</i> overexpression predicts response to anthracycline+cyclophosphamide and survival in triple-negative breast cancers. <i>Molecular Oncology</i> , 2023, 17, 2017-2028.           | 2.1  | 2         |
| 193 | The WAVE3/ $\beta$ -catenin oncogenic signaling regulates chemoresistance in triple negative breast cancer. <i>Breast Cancer Research</i> , 2023, 25, .                                      | 2.2  | 2         |
| 194 | Triple-Negative Breast Cancer: Basic Biology and Immuno-Oncolytic Viruses. <i>Cancers</i> , 2023, 15, 2393.  | 1.7  | 2         |